|
12th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine.
|
|
2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women
|
Other
|
AHRQ, CDC, FDA, HRSA, OASH
|
OD/DPCPSI/ORWH, CC, CSR, NCATS, NCCIH, FIC, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/AoU, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ODSS, OD/DPCPSI/OEPR, OD/DPCPSI/ONR, OD/DPCPSI/SGMRO
|
The Office of Research on Women’s Health (ORWH) is responsible for an NIH-wide strategic plan on research on the health of women that promotes allocation of NIH resources for conducting and supporting research efforts on the health of women across NIH Institutes and Centers. ORWH is currently undergoing the process of updating the NIH-Wide Strategic Plan for Research on the Health of Women. Recent, significant public health events (e.g., the COVID pandemic) have had an outsized effect on the health of women. Several topics relevant to the health of women were reviewed by the NIH and the NIH Advisory Committee on Research on Women’s Health (ACRWH) in 2021, through the congressionally directed and ORWH-led Women’s Health Conference. This convening included a review of NIH activities to identify research opportunities to address maternal mortality and morbidity, survival rates of cervical cancer, and chronic and debilitating diseases in women. The recommendations that the ACRWH made consequent to this conference as well as recent scientific advances; new technologies; current health priorities; and feedback from a Request for Information will all be considered in the development of the next NIH-Wide Strategic Plan for Research on the Health of Women to help guide future NIH research efforts to improve the health of all women throughout the entire life course. NIH published a Notice (NOT-OD-22-186) to solicit input from the basic, clinical, and translational scientists; advocacy and patient communities; and the public on topics under consideration for the next strategic plan. ORWH established NIH, HHS, and VA engagement in the development of the 2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women that will be released in 2024.
|
|
3D Bioprinted skin models for drug screening
|
Research Initiative
|
FDA
|
NCATS
|
3D Bioprinted skin models for drug screening
|
|
4th National Conference on Advancing Early Psychosis Care in the United States: Harnessing Resiliency in a Changing World
|
Meeting/ Workshop
|
SAMHSA
|
NIMH
|
The National Institute of Mental Health (NIMH), in collaboration with the Substance Abuse and Mental Health Services Administration (SAMHSA) through its National Training and Technical Assistance Center sponsored a meeting entitled, "Advancing Early Psychosis Care in the United States: Harnessing Resiliency in a Changing World," on March 10-11, 2022. With the rapid expansion of evidence-based early psychosis care in the United States, largely the result of the successful NIMH-funded Recovery After an Initial Schizophrenia Episode (RAISE) initiative, additional clinician training on early psychosis is needed. Thousands of clinicians and other professionals working in the early psychosis care field attended the virtual event. NIMH staff served on the planning committee and as presenters.
|
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
Research Initiative
|
FDA
|
NCI
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and prostate cancer
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and renal cell carcinoma
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and uterine and ovarian cancers
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for nested case-control studies of endometrial (uterine) and ovarian cancers in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A nested case-control study of serum PFAS and testicular cancer in Air Force servicemen
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) is collaborating with Uniformed Services University of the Health Sciences (USUHS) and Centers for Disease Control and Prevention (CDC) on a nested case-control study measuring serum PFAS concentrations among Air Force servicemen with samples in the Department of Defense Serum Repository.
|
|
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease
|
Research Initiative
|
FDA
|
NHLBI
|
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease
|